

NB-003: CD38-Targeting Antibody




A first-in-class humanized monoclonal antibody targeting CD38 for the treatment of multiple myeloma (MM) and autoimmune diseases. With FDA IND approval secured, this program addresses an \$8B market opportunity with strong global patent protection.

NB-003: First-in-Class CD38-Targeting Antibody

Program Overview

NB-003 is a first-in-class humanized monoclonal antibody targeting CD38 for the treatment of multiple myeloma (MM) and autoimmune diseases. With **FDA IND approval** secured, this program addresses an **\$8B market opportunity** with strong global patent protection.



Differentiated Targeting

Unlike daratumumab and isatuximab, NB-003 recognizes and binds to a unique epitope on CD38 with **negligible red blood cell (RBC) binding**, potentially eliminating interference with blood banking procedures and reducing infusion-related reactions.

Multiple Myeloma

Primary indication leveraging potent tumor suppression and strong direct apoptotic activity

Autoimmune Expansion

Clinical validation of CD38 in lupus nephritis creates pathway for indication expansion


Enhanced ADCC

Superior antibody-dependent cellular cytotoxicity drives robust tumor-killing activity

NB-003: Differentiated Mechanism, Superior Activity

Unique Epitope Recognition

NB-003 is a humanized IgG1 monoclonal antibody that targets a **differentiated epitope of CD38** distinct from existing approved therapies. This unique binding profile results in negligible RBC binding compared to daratumumab and isatuximab, addressing a key limitation of current CD38-directed therapies that can interfere with blood compatibility testing.



Expanded Therapeutic Potential

Beyond multiple myeloma, CD38 represents a **clinically validated target for autoimmune diseases**, as demonstrated by daratumumab's efficacy in lupus nephritis. NB-003's superior safety profile—particularly its minimal RBC binding—positions it as an exceptionally strong candidate for indication expansion into autoimmune disorders where chronic dosing and safety considerations are paramount.

Accelerating Innovation to Improve Patients' Lives

Navika Bio connects groundbreaking biotech innovation with global pharmaceutical partners to deliver transformative therapies to patients worldwide.



Let's Connect

For more information about partnership opportunities and to join us on this exciting journey of bringing transformative therapies to patients worldwide, please reach out to:



Lawrence Hu, PhD

**Chief Technology Officer
Head of Business Development**

Phone: 973-967-9949

Email: lawrence@navikabio.com

